氯吡格雷,临床注释-2,变异和临床注释数据

氯吡格雷

临床注释ID

1451282340

药物名称(英)

clopidogrel

变异单倍型

CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17

基因

CYP2C19

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Efficacy

表现型类别

功效

分数

384.625

PMID计数

100

计数的证据

159

表现型

心血管疾病

表现型(英)

Cardiovascular Diseases

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1451282340

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1285	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a no or decreased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.
1284	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.
1283	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.
1282	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with a normal function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation compared to patients with two increased function alleles or a combination of a normal function allele with an increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.

临床证据

id	证据的ID	总结
1513	1183681446	CYP2C19 1/1 + 1/17 + 2/17 + 3/17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 1/2 + 1/3 + 2/2 + 2/3 + 3/3.
1512	1183631808	CYP2C19 3 is associated with increased on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 1/*1.
1511	1183631797	CYP2C19 2 is associated with increased On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 1/*1.
1510	1183491857	CYP2C19 1/1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/2 + 2/2.
1509	1043818382	CYP2C19 3 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 1/*1.
1508	1043818375	CYP2C19 2 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 1/*1.
1507	1043818357	CYP2C19 3 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 1/*1.
1506	1043818349	CYP2C19 2 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 1/*1.
1505	982047486	CYP2C19 17 is not associated with increased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 1.
1504	982047473	CYP2C19 2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 1.
1503	982042102	CYP2C19 17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 1.
1502	982042094	CYP2C19 2 is associated with increased post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 1.
1501	982023653	CYP2C19 3 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 1.
1500	982023647	CYP2C19 2 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 1.
1499	981802889	CYP2C19 3 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 1.
1498	981802868	CYP2C19 2 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 1.
1497	827814107	CYP2C19 *17 is associated with decreased likelihood of platelet reactivity when treated with clopidogrel in people with Angina Pectoris.
1496	981478609	CYP2C19 3 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 1.
1495	981478604	CYP2C19 2 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 1.
1494	1450129827	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1493	1449192147	Genotype AG is associated with increased platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype AA.
1492	1448258595	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1491	1444702829	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1490	1184472508	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1489	1184470036	Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.
1488	1184470005	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1487	1183702397	Genotypes AA + AG is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1486	769245465	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.
1485	769245456	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.
1484	827919768	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.
1483	827823391	Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.
1482	827815433	Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1481	827787114	Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.
1480	827784103	Allele A is associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele G.
1479	827784087	Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.
1478	1043765400	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.
1477	1043762214	Genotypes AA + AG are associated with increased risk of insufficient antiplatelet response to clopidogrel when treated with clopidogrel in patients undergoing elective coronary stent implantation as compared to genotype GG.
1476	1043760981	Genotypes AA + AG are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel as compared to genotype GG.
1475	1029227540	Genotypes AA + AG are associated with increased platelet reactivity when treated with clopidogrel in PCI-scheduled patients as compared to genotype GG.
1474	982037635	Allele A is associated with high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.
1473	982035424	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.
1472	982034718	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.
1471	982034621	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1470	982034526	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.
1469	982034249	Allele A is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.
1468	982033674	Genotypes AA + AG are associated with increased risk of high-on clopidogrel platelet reactivity when treated with clopidogrel in patients undergoing elective coronary stent placement as compared to genotype GG.
1467	982033630	Allele A is associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
1466	982033525	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.
1465	982033484	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.
1464	982033431	Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.
1463	982033160	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1462	982033103	Genotypes AA + AG are associated with increased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1461	982032787	Allele A is associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to allele G.
1460	982029072	Allele A is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.
1459	981844125	Allele A is not associated with decreased platelet inhibition when treated with clopidogrel as compared to genotype GG.
1458	981844094	Genotypes AA + AG are associated with increased residual platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1457	981844053	Genotypes AA + AG are associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1456	981843471	Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.
1455	981802548	Allele A is associated with decreased platelet inhibition when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1454	981801214	Allele A is associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1453	981344377	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1452	981344366	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1451	1448258608	Genotype AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1450	827919808	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.
1449	1043818407	Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.
1448	1043765783	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.
1447	982035447	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.
1446	982034728	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.
1445	982034575	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.
1444	982034226	Allele A is associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.
1443	982033614	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.
1442	982033598	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.
1441	981344408	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1440	981344388	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1439	1448258619	Genotypes CT + TT are not associated with response to clopidogrel in people with Acute coronary syndrome.
1438	1184470013	Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.
1437	1184469584	Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.
1436	699638703	Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.
1435	769245459	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.
1434	769245468	Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.
1433	827919816	Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.
1432	827815445	Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.
1431	982033119	Genotypes CT + TT are associated with decreased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.
1430	982033044	Genotype CC is associated with greater platelet inhibition 2 h after a 600-mg dose when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.
1429	981344520	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.
1428	1447986842	Genotypes AA + AG are associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.
1427	1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.
1426	PA166104948	Annotation of CPIC Guideline for clopidogrel and CYP2C19
1228	1450664799	CYP2C19 2/2 is associated with increased platelet reactivity when treated with clopidogrel in people with Angina Pectoris.
1227	1450664741	CYP2C19 2/2 + 2/3 are associated with increased high on-treatment platelet reactivity when treated with clopidogrel in healthy individuals as compared to CYP2C19 1/1.
1226	1450370841	CYP2C19 1/2 + 2/2 + 2/17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C19 1/1 + 1/17 + 17/17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .
1225	1450253685	CYP2C19 2 + 3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1224	1449712939	CYP2C19 2 is associated with increased platelet aggregation when treated with aspirin and clopidogrel as compared to CYP2C19 1 + *17.
1223	1449296254	CYP2C19 *2 is associated with decreased response to clopidogrel.
1222	1449187754	CYP2C19 2 is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/*1.
1221	1449187738	CYP2C19 3 is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/*1.
1220	1448634534	CYP2C19 1 + 17 are associated with decreased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *2.
1219	1448634286	CYP2C19 1/1 is associated with decreased platelet aggregation when treated with aspirin and clopidogrel in people with Acute coronary syndrome and Myocardial Infarction as compared to CYP2C19 1/2 + 2/2.
1218	1448633804	CYP2C19 17 is not associated with response to clopidogrel as compared to CYP2C19 1/*1.
1217	1448633755	CYP2C19 3 is not associated with decreased response to clopidogrel as compared to CYP2C19 1/*1.
1216	1448633744	CYP2C19 1/17 is associated with increased platelet aggregation inhibition when treated with clopidogrel as compared to CYP2C19 1/1.
1215	1448633723	CYP2C19 2 is associated with decreased response to clopidogrel as compared to CYP2C19 1/*1.
1214	1448631999	CYP2C19 2/2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 1/1 + 1/2.
1213	1448603378	CYP2C19 17 is associated with decreased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 1/*1.
1212	1448603367	CYP2C19 2 is associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 1/*1.
1211	1448119221	CYP2C19 2 + 3 are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 1/1.
1210	1448115828	CYP2C19 17 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 1.
1209	1448112663	CYP2C19 2 is associated with decreased response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 1.
1208	1446899066	CYP2C19 2 + 4 are associated with decreased response to clopidogrel as compared to CYP2C19 1 + 17.
1207	1445296466	CYP2C19 1/1 is associated with decreased platelet reactivity when treated with clopidogrel in people with as compared to CYP2C19 1/2 + 1/3 + 2/2 + 2/3 + 3/3.
1206	1445296396	CYP2C19 17/17 + 1/17 are associated with increased platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP2C19 1/1.
1205	1444936352	CYP2C19 17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1.
1204	1444936339	CYP2C19 2/2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1 + 1/2.
1203	1444706449	CYP2C19 2 + 3 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1202	1444706434	CYP2C19 2 + 3 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1201	1444706389	CYP2C19 2 + 3 is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 1/1.
1200	1444704692	CYP2C19 2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/*1.
1199	1444704608	CYP2C19 1/2 + 2/2 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1 + 1/17 + 17/17.
1198	1444702906	CYP2C19 2 is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 1/*1.
1197	1444701722	CYP2C19 2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/*1.
1196	1444701710	CYP2C19 2 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/*1.
1195	1444701698	CYP2C19 2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 1.
1194	1444667887	CYP2C19 2/2 + 3/3 + 2/3 (assigned as poor metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 1/1 (assigned as normal metabolizer phenotype) .
1193	1444667855	CYP2C19 1/2 + 1/3 (assigned as intermediate metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 1/1 (assigned as normal metabolizer phenotype) .
1192	1444607076	CYP2C19 1/2 + 2/2 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1191	1184987661	CYP2C19 3 is associated with decreased response to clopidogrel as compared to CYP2C19 1.
1190	1184987641	CYP2C19 2 is associated with decreased response to clopidogrel as compared to CYP2C19 1.
1189	1184473190	CYP2C19 2/2 + 1/2 is associated with increased ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 1/1.
1188	1184473178	CYP2C19 2/2 is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 1/1.
1187	1184472379	CYP2C19 2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1.
1186	1184472347	CYP2C19 2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1.
1185	1184472114	CYP2C19 1/17 + 17/17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1.
1184	1184470291	CYP2C19 2/2 + 2/3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 1/1.
1183	1184469934	CYP2C19 1/2 + 1/8 + 2/2 (assigned as poor metabolizer genotype phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1 + 1/17 + 17/17 (assigned as normal metabolizer genotype phenotype) .
1182	1184469836	CYP2C19 2/2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 2/3.
1181	1184469816	CYP2C19 1/2 + 1/3 + 2/2 + 2/3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 1/1.
1180	1184469799	CYP2C19 1/2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 1/3.
1179	1184349853	CYP2C19 2 is associated with increased platelet reactivity by P2Y12 reaction units when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 1/*1.
1178	1184349199	CYP2C19 1/2 is associated with increased platelet aggregation with ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1177	1184349010	CYP2C19 1/2 + 2/17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 1/17 + 17/17.
1176	1184348998	CYP2C19 1/2 + 2/17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 1/1.
1175	1184348932	CYP2C19 1/2 + 1/3 + 2/2 + 2/3 + 3/3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1.
1174	1184348910	CYP2C19 1/2 + 1/3 + 2/2 + 2/3 + 3/3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1.
1173	1184168878	CYP2C19 1/17 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1172	1184168856	CYP2C19 1/3 + 3/3 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1171	1184168844	CYP2C19 1/2 + 1/3 + 2/2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1170	1184168830	CYP2C19 1/2 + 2/2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1169	1183848900	CYP2C19 1/17 + 1/2 + 17/17 + 2/17 are not associated with platelet aggregation activity as measured by the VerifyNow P2Y12 test when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1.
1168	1183705597	CYP2C19 2 + 3 are associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 1/1.
1167	1183704635	CYP2C19 1/3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 1/2.
1166	1183704627	CYP2C19 1/3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 1/1.
1165	1183704618	CYP2C19 1/2 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 1/1.
1164	1183703514	CYP2C19 2 + 3 is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 1/1.
1163	1183702492	CYP2C19 1/2 + 2/2 is associated with increased risk of high platelet reactivity when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 1/1.
1162	1183702381	CYP2C19 1/2 + 2/2 is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 1/1.
1161	1183697317	CYP2C19 1/2 + 1/3 (assigned as intermediate metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 1/1 + 1/17 (assigned as normal metabolizer phenotype) .
1160	1183697283	CYP2C19 2/2 + 2/3 + 3/3 (assigned as poor metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 1/1 + 1/17 (assigned as normal metabolizer phenotype) .
1159	1183689255	CYP2C19 2 + 3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.
1158	1183681642	CYP2C19 2/2 + 2/3 + 3/3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.

临床病史

id	类型	评论
1408	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1407	Create	Created
1406	Update	combined clopidogrel only and 'aspirin and clopidogrel' VAs given that clopidogrel is mainly given in combination with aspirin; Merged PA981201917, PA655384520 into star allele CA

最新招商产品更多>>